These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 29847547)

  • 1. Clustered intergenic region sequences as predictors of factor H Binding Protein expression patterns and for assessing Neisseria meningitidis strain coverage by meningococcal vaccines.
    Cayrou C; Akinduko AA; Mirkes EM; Lucidarme J; Clark SA; Green LR; Cooper HJ; Morrissey J; Borrow R; Bayliss CD
    PLoS One; 2018; 13(5):e0197186. PubMed ID: 29847547
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Meningococcal Outer Membrane Vesicle Vaccine with Overexpressed Mutant FHbp Elicits Higher Protective Antibody Responses in Infant Rhesus Macaques than a Licensed Serogroup B Vaccine.
    Beernink PT; Vianzon V; Lewis LA; Moe GR; Granoff DM
    mBio; 2019 Jun; 10(3):. PubMed ID: 31213564
    [TBL] [Abstract][Full Text] [Related]  

  • 3. From research to licensure and beyond: clinical development of MenB-FHbp, a broadly protective meningococcal B vaccine.
    Perez JL; Absalon J; Beeslaar J; Balmer P; Jansen KU; Jones TR; Harris S; York LJ; Jiang Q; Radley D; Anderson AS; Crowther G; Eiden JJ
    Expert Rev Vaccines; 2018 Jun; 17(6):461-477. PubMed ID: 29883226
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Meningococcal serogroup B vaccines: Estimating breadth of coverage.
    Donald RG; Hawkins JC; Hao L; Liberator P; Jones TR; Harris SL; Perez JL; Eiden JJ; Jansen KU; Anderson AS
    Hum Vaccin Immunother; 2017 Feb; 13(2):255-265. PubMed ID: 27960595
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characteristics of a new meningococcal serogroup B vaccine, bivalent rLP2086 (MenB-FHbp; Trumenba®).
    Gandhi A; Balmer P; York LJ
    Postgrad Med; 2016 Aug; 128(6):548-56. PubMed ID: 27467048
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase Variation of NadA in Invasive Neisseria meningitidis Isolates Impacts on Coverage Estimates for 4C-MenB, a MenB Vaccine.
    Green LR; Lucidarme J; Dave N; Chan H; Clark S; Borrow R; Bayliss CD
    J Clin Microbiol; 2018 Sep; 56(9):. PubMed ID: 29950334
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neisseria meningitidis Urethritis Outbreak Isolates Express a Novel Factor H Binding Protein Variant That Is a Potential Target of Group B-Directed Meningococcal (MenB) Vaccines.
    Tzeng YL; Giuntini S; Berman Z; Sannigrahi S; Granoff DM; Stephens DS
    Infect Immun; 2020 Nov; 88(12):. PubMed ID: 32958529
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic Diversity of Meningococcal Serogroup B Vaccine Antigens among Carriage Isolates Collected from Students at Three Universities in the United States, 2015-2016.
    Marjuki H; Chang HY; Topaz N; Whaley MJ; Vuong J; Chen A; Jenkins LT; Hu F; Schmink S; Retchless AC; Thomas JD; Acosta AM; McNamara LA; Soeters HM; Mbaeyi S; Wang X
    mBio; 2021 May; 12(3):. PubMed ID: 34006659
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Breadth and Duration of Meningococcal Serum Bactericidal Activity in Health Care Workers and Microbiologists Immunized with the MenB-FHbp Vaccine.
    Lujan E; Partridge E; Giuntini S; Ram S; Granoff DM
    Clin Vaccine Immunol; 2017 Aug; 24(8):. PubMed ID: 28566335
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A meningococcal NOMV-FHbp vaccine for Africa elicits broader serum bactericidal antibody responses against serogroup B and non-B strains than a licensed serogroup B vaccine.
    Pajon R; Lujan E; Granoff DM
    Vaccine; 2016 Jan; 34(5):643-649. PubMed ID: 26709637
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Binding of complement factor H to PorB3 and NspA enhances resistance of Neisseria meningitidis to anti-factor H binding protein bactericidal activity.
    Giuntini S; Pajon R; Ram S; Granoff DM
    Infect Immun; 2015 Apr; 83(4):1536-45. PubMed ID: 25644002
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of fHbp, nhba (gna2132), nadA, porA, and sequence type in group B meningococcal case isolates collected in England and Wales during January 2008 and potential coverage of an investigational group B meningococcal vaccine.
    Lucidarme J; Comanducci M; Findlow J; Gray SJ; Kaczmarski EB; Guiver M; Vallely PJ; Oster P; Pizza M; Bambini S; Muzzi A; Borrow R
    Clin Vaccine Immunol; 2010 Jun; 17(6):919-29. PubMed ID: 20375242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distribution of Bexsero® Antigen Sequence Types (BASTs) in invasive meningococcal disease isolates: Implications for immunisation.
    Brehony C; Rodrigues CMC; Borrow R; Smith A; Cunney R; Moxon ER; Maiden MCJ
    Vaccine; 2016 Sep; 34(39):4690-4697. PubMed ID: 27521232
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-Factor H Antibody Reactivity in Young Adults Vaccinated with a Meningococcal Serogroup B Vaccine Containing Factor H Binding Protein.
    Sharkey K; Beernink PT; Langley JM; Gantt S; Quach C; Dold C; Liu Q; Galvan M; Granoff DM
    mSphere; 2019 Jul; 4(4):. PubMed ID: 31270173
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Susceptibility of Meningococcal Strains Responsible for Two Serogroup B Outbreaks on U.S. University Campuses to Serum Bactericidal Activity Elicited by the MenB-4C Vaccine.
    Rossi R; Beernink PT; Giuntini S; Granoff DM
    Clin Vaccine Immunol; 2015 Dec; 22(12):1227-34. PubMed ID: 26424832
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Meningococcal Factor H Binding Protein Vaccine Antigens with Increased Thermal Stability and Decreased Binding of Human Factor H.
    Rossi R; Konar M; Beernink PT
    Infect Immun; 2016 Jun; 84(6):1735-1742. PubMed ID: 27021245
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diversity of Canadian meningococcal serogroup B isolates and estimated coverage by an investigational meningococcal serogroup B vaccine (4CMenB).
    Bettinger JA; Scheifele DW; Halperin SA; Vaudry W; Findlow J; Borrow R; Medini D; Tsang R;
    Vaccine; 2013 Dec; 32(1):124-30. PubMed ID: 23588089
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical data supporting a 2-dose schedule of MenB-FHbp, a bivalent meningococcal serogroup B vaccine, in adolescents and young adults.
    Beeslaar J; Absalon J; Balmer P; Srivastava A; Maansson R; York LJ; Perez JL
    Vaccine; 2018 Jun; 36(28):4004-4013. PubMed ID: 29861182
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estimated susceptibility of Canadian meningococcal B isolates to a meningococcal serogroup B vaccine (MenB-FHbp).
    Bettinger JA; Liberator P; Halperin SA; Vaudry W; Sadarangani M; Hao L; Lambert N; Jansen KU; Anderson AS; Tsang R;
    Vaccine; 2020 Feb; 38(8):2026-2033. PubMed ID: 31983586
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Development of a Vaccine Against Meningococcus B Using Reverse Vaccinology.
    Masignani V; Pizza M; Moxon ER
    Front Immunol; 2019; 10():751. PubMed ID: 31040844
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.